These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer. Hu Q; Jagusch C; Hille UE; Haupenthal J; Hartmann RW J Med Chem; 2010 Aug; 53(15):5749-58. PubMed ID: 20684610 [TBL] [Abstract][Full Text] [Related]
30. The role of fluorine substitution in biphenyl methylene imidazole-type CYP17 inhibitors for the treatment of prostate carcinoma. Hu Q; Negri M; Olgen S; Hartmann RW ChemMedChem; 2010 Jun; 5(6):899-910. PubMed ID: 20437447 [TBL] [Abstract][Full Text] [Related]
31. The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors. Jarman M; Barrie SE; Llera JM J Med Chem; 1998 Dec; 41(27):5375-81. PubMed ID: 9876107 [TBL] [Abstract][Full Text] [Related]
32. Oxazolinyl derivatives of [17(20)E]-21-norpregnene differing in the structure of A and B rings. Facile synthesis and inhibition of CYP17A1 catalytic activity. Kostin VA; Zolottsev VA; Kuzikov AV; Masamrekh RA; Shumyantseva VV; Veselovsky AV; Stulov SV; Novikov RA; Timofeev VP; Misharin AY Steroids; 2016 Nov; 115():114-122. PubMed ID: 27505042 [TBL] [Abstract][Full Text] [Related]
33. Synthesis and molecular docking of 1,2,3-triazole-based sulfonamides as aromatase inhibitors. Pingaew R; Prachayasittikul V; Mandi P; Nantasenamat C; Prachayasittikul S; Ruchirawat S; Prachayasittikul V Bioorg Med Chem; 2015 Jul; 23(13):3472-80. PubMed ID: 25934226 [TBL] [Abstract][Full Text] [Related]
34. Novel steroidal vinyl fluorides as inhibitors of steroid C17(20) lyase. Burkhart JP; Weintraub PM; Gates CA; Resvick RJ; Vaz RJ; Friedrich D; Angelastro MR; Bey P; Peet NP Bioorg Med Chem; 2002 Apr; 10(4):929-34. PubMed ID: 11836100 [TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and structure-activity relationships of azolylmethylpyrroloquinolines as nonsteroidal aromatase inhibitors. Ferlin MG; Carta D; Bortolozzi R; Ghodsi R; Chimento A; Pezzi V; Moro S; Hanke N; Hartmann RW; Basso G; Viola G J Med Chem; 2013 Oct; 56(19):7536-51. PubMed ID: 24025069 [TBL] [Abstract][Full Text] [Related]
36. Synthesis of 3beta, 7alpha, 11alpha-trihydroxy-pregn-21-benzylidene-5-en-20-one derivatives and their cytotoxic activities. Shan LH; Liu HM; Huang KX; Dai GF; Cao C; Dong RJ Bioorg Med Chem Lett; 2009 Dec; 19(23):6637-9. PubMed ID: 19864129 [TBL] [Abstract][Full Text] [Related]
37. Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors. Moreira VM; Vasaitis TS; Njar VC; Salvador JA Steroids; 2007 Dec; 72(14):939-48. PubMed ID: 17884122 [TBL] [Abstract][Full Text] [Related]
38. Molecular modeling on inhibitor complexes and active-site dynamics of cytochrome P450 C17, a target for prostate cancer therapy. Haider SM; Patel JS; Poojari CS; Neidle S J Mol Biol; 2010 Jul; 400(5):1078-98. PubMed ID: 20595043 [TBL] [Abstract][Full Text] [Related]
39. Differential inhibition of 17alpha-hydroxylase and 17,20-lyase activities by three novel missense CYP17 mutations identified in patients with P450c17 deficiency. Van Den Akker EL; Koper JW; Boehmer AL; Themmen AP; Verhoef-Post M; Timmerman MA; Otten BJ; Drop SL; De Jong FH J Clin Endocrinol Metab; 2002 Dec; 87(12):5714-21. PubMed ID: 12466376 [TBL] [Abstract][Full Text] [Related]
40. Synthesis and evaluation of pregnane derivatives as inhibitors of human testicular 17 alpha-hydroxylase/C17,20-lyase. Li JS; Li Y; Son C; Brodie AM J Med Chem; 1996 Oct; 39(21):4335-9. PubMed ID: 8863811 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]